Biocartis is an innovative molecular diagnostics company committed to revolutionize molecular testing with its unique proprietary IdyllaTM platform. We provide next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus on oncology.
Biocartis’ proprietary molecular diagnostics (MDx) IdyllaTM platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample, in virtually any setting, allowing fast and effective treatment selection and treatment progress monitoring.
Upcoming eventsAll events
1212 '23Event by: Eurasanté
0602 '24Event by: Ghent University, Provaxs, Paul Dick & Associates
3011 '23Event by: Advipro
Latest newsMore news
argenx reports topline results from ADVANCE-SC study of VYVGART Hytrulo in primary immune thrombocytopenia
21 hours ago
Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion
Wednesday November 22nd 2023
argenx announces European Commission approval of subcutaneous VYVGART® (efgartigimod alfa) for generalized myasthenia gravis
Thursday November 16th 2023
Antwerp, Brussels, East Flanders, Hainaut, Liège, Limburg, Luxembourg, Namur, Flemish Brabant, Walloon Brabant, West Flanders, Remote
PermanentThema Group Belgium